Drug Profile
BP 1249
Alternative Names: Atopic dermatitis therapy - Bridge PharmaLatest Information Update: 28 May 2007
Price :
$50
*
At a glance
- Originator Bridge Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 10 Jun 2002 A new agreement between Bridge Pharma and Immune Network has been signed following termination of 50:50 joint venture
- 15 Feb 2001 BP 1249 has been selected as the lead drug candidate from Bridge Pharma and Immune Network's atopic dermatitis research programme
- 23 May 2000 Preclinical development for Atopic dermatitis in USA (Unknown route)